enow.com Web Search

Search results

  1. Results from the WOW.Com Content Network
  2. Hyperphosphatemia - Wikipedia

    en.wikipedia.org/wiki/Hyperphosphatemia

    Diagnosis is generally based on a blood phosphate level exceeding 1.46 mmol/L (4.5 mg/dL). [1] Levels may appear falsely elevated with high blood lipid levels, high blood protein levels, or high blood bilirubin levels. [1] Treatment may include a phosphate low diet and antacids like calcium carbonate that bind phosphate. [1]

  3. US FDA approves Ardelyx's kidney disease-related drug - AOL

    www.aol.com/news/us-fda-approves-ardelyxs-kidney...

    (Reuters) -The U.S. Food and Drug Administration (FDA) has approved Ardelyx's drug to treat high phosphate levels in patients with chronic kidney disease (CKD), the company said on Tuesday, more ...

  4. Unicycive Therapeutics Announces U.S. FDA Acceptance of the ...

    lite.aol.com/tech/story/0022/20241111/9270851.htm

    Treatment of hyperphosphatemia is aimed at lowering serum phosphate levels via two means: (1) restricting dietary phosphorus intake; and (2) using, on a daily basis, and with each meal, oral phosphate binding drugs that facilitate fecal elimination of dietary phosphate rather than its absorption from the gastrointestinal tract into the bloodstream.

  5. Elevated alkaline phosphatase - Wikipedia

    en.wikipedia.org/wiki/Elevated_alkaline_phosphatase

    Treatment of the underlying condition. Once doctors identify the cause of elevated ALP and diagnose a treatment, the levels of alkaline phosphatase fluctuates back to normal; Removal of medication. Drugs can be associated with increased levels of alkaline phosphatase, including: Birth control pills; Anti-inflammatory medication; Narcotic medication

  6. RenaZorb is an orally available, lanthanum-based nanotechnology compound being developed for the potential treatment of high phosphate blood levels in patients with Stage 5 chronic kidney disease.

  7. Colestilan - Wikipedia

    en.wikipedia.org/wiki/Colestilan

    Colestilan (INN, trade name BindRen) is a medication that acts as a phosphate binder [1] and bile acid sequestrant. [2] It is an ion-exchange resin, is an orally administered bile acid sequestrant that is being developed by Mitsubishi Tanabe Pharma Corporation for the treatment of hypercholesterolaemia and hyperphosphataemia.

  8. Ardelyx sues US health department over kidney disease drug - AOL

    www.aol.com/news/ardelyx-sues-us-health...

    The lawsuit claims that CMS's plan to include the drug, Xphozah, along with all other oral-only phosphate lowering therapies in the End-Stage Renal Disease Prospective Payment System (ESRD) will ...

  9. Sucroferric oxyhydroxide - Wikipedia

    en.wikipedia.org/wiki/Sucroferric_oxyhydroxide

    Sucroferric oxyhydroxide, sold under the brand name Velphoro, is a non-calcium, iron-based phosphate binder used for the control of serum phosphorus levels in adults with chronic kidney disease (CKD) on hemodialysis (HD) or peritoneal dialysis (PD). [6] It is used in form of chewable tablets. [5]